Greenwich LifeSciences, Inc.

GLSI

US3968791083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:06:16 2024-05-15 pm EDT			5-day change	1st Jan Change
14.42 ^USD	+5.68%		+5.70%	+37.35%

Apr. 15	Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ

GREENWICH LIFESCIENCES, INC. : Other Events (form 8-K)

March 13, 2023 at 06:08 am EDT

Item 8.01 Other Events.

Greenwich LifeSciences, Inc. informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.

-2-

Latest news about Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing	Mar. 07	MT
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe	Feb. 22	MT
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators	Feb. 22	CI
HC Wainwright Adjusts Greenwich LifeSciences Price Target to $36 From $38, Maintains Buy Rating	Feb. 20	MT
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01	Feb. 14	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	Feb. 14	MT
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment	Feb. 14	MT
Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy	Feb. 14	DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-19	CI
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech	23-08-25	DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
North American Morning Briefing : Stocks to Extend -3-	23-05-18	DJ
Greenwich Lifesciences, Inc. Confirms the Interest in Both of Itsgp2 Phase Iib Clinical Trial and Phase Iii Clinical Trial, Flamingo-01	23-04-13	CI
HC Wainwright Cuts Greenwich LifeSciences' Price Target to $38 From $78, Keeps Buy Rating	23-04-10	MT
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
North American Morning Briefing : Traders Await -3-	23-03-31	DJ
North American Morning Briefing : Stock Futures -2-	23-03-24	DJ
North American Morning Briefing : Focus on Bank -2-	23-03-17	DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) dropped from S&P Global BMI Index	22-09-19	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Greenwich LifeSciences Launches Late-Stage Breast Cancer Trial	22-08-11	MT

Chart Greenwich LifeSciences, Inc.

Duration

Period

More charts

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.64 USD

Average target price

36 USD

Spread / Average Target

+163.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GREENWICH LIFESCIENCES, INC.	+37.35%	176M
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-8.61%	33.03B
UCB	+55.32%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-16.41%	15.12B
INCYTE CORPORATION	-8.88%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	8.9B

Biopharmaceuticals